The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Novo said in a statement it wanted to ensure patients only received FDA-approved, safe, and effective semaglutide products.

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Compounded semaglutide: Medication produced by compounded pharmacies ... A telehealth provider that can prescribe GLP-1 ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Novo Nordisk has raised alarm about safety concerns related to compounded versions of its semaglutide-based drugs, Wegovy and Ozempic. The pharmaceuticals giant acknowledged reports of 10 deaths and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes ... Scott Brunner, CEO of the Alliance for ...

You can now get a prescription for weight loss drugs like Ozempic from an online telehealth Visit. But iis it safe?"It’s hard ...